The treatment of advanced renal cell carcinoma has been completely changed by the development of new therapeutic modalities during the past 3 years. In this time period six targeted agents have been approved for the treatment of advanced or metastatic disease. Phase 3 data support the use of sunitinib, bevacizumab plus interferon-a and pazopanib for patients with low and intermediate risk of clear-cell renal cell carcinoma. In the pivotal study of temsirolimus a significant longer overall survival compared with interferon-a in high-risk disease including non-clear-cell histology was observed. Patients pretreated with cytokines will benefit from sorafenib and pazopanib while everolimus has been shown to increase significantly progression-free survival after previous anti-angiogenesis therapy. In addition to these phase 3 data-based recommendations, several other factors have to be considered for treatment selection, for example, side effect profile and patients' comorbidities. Currently, the sequential use of the available targeted drugs and adjuvant treatment are the subject of ongoing clinical trials. However, medical treatment of renal cell carcinoma remains palliative and surgery remains the only curative approach in patients with localized, locally advanced and limited metastatic disease.
Introduction
Kidney cancer has an estimated number of 208,000 new cases (about 2% of all cancer cases) and causes 102,000 cancer deaths worldwide annually [Parkin et al. 2005] . About 7585% of the tumors are clear-cell renal cell carcinomas (ccRCC), while papillary (1214%), chromophic (46%), and other types of RCC are less common [Linehan et al. 2003 ]. Of the patients suffering from RCC about one quarter already have metastases at diagnosis and another quarter will develop metastatic disease despite complete surgical removal of the primary tumor.
Advanced and metastatic RCC (mRCC) is considered to be particularly resistant to conventional chemotherapy and radiotherapy. Therefore, treatment is difficult and cure is almost impossible when surgery is unable to eradicate the disease [de Reijke et al. 2009 ]. Until 2006 immunotherapy using interferon-2a and/or interleukin-2 was commonly used for the treatment of mRCC. However, treatment effects were very limited while immunotherapy was associated with significant side effects.
In recent years, several new drugs have been developed which interfere with altered molecular pathways, for example, tumor angiogenesis, of this special tumor entity. The monoclonal antibody bevacizumab binds and inactivates the vascular endothelial growth factor thus preventing activation of the respective receptor.
Sorafenib, sunitinib and pazopanib are orally administered multikinase inhibitors with a similar but not identical spectrum of molecular targets. The drugs block vascular endothelial growth factor receptors 13 (VEGFR 13), plateletderived growth factor receptor b, FMS-like tyrosine kinase 3 (Flt-3) and c-Kit. Sorafenib further interacts with the downstream signaling cascade of the mitogen-activated protein kinases pathway by inhibiting the serine-threonine kinase Raf-1.
The mammalian target of rapamycine (mTOR) plays an important role in downstream signaling cascades, thus regulating cell cycle, proliferation, and apoptosis. Temsirolimus and its orally applied derivative everolimus inhibit this serine-threonine protein kinase and have been approved for the treatment of advanced RCC [Motzer et al. 2008; Hudes et al. 2007 ].
The approval of these new drugs (and several others are currently being evaluated in clinical phase 2 and 3 studies) has fundamentally changed the treatment of RCC. Since there are at least six different drugs and even more sequential treatment options currently available, selection of the right treatment strategy became the new challenge. Furthermore, patients included in clinical trials only represent to a limited degree patients in everyday clinical practice. We discuss treatment aims, different drugs and side effects, particular patient cohorts (e.g. elderly patients, non-ccRCC), the use of sequential therapy, and introduce ongoing adjuvant trials.
Treatment aims
Despite a significant improvement achieved with the new drugs, surgical removal of the entire tumor remains the only curative treatment option. Therefore, surgery is the treatment of choice in patients with localized, locally advanced (including lymph node positive disease), and limited metastatic disease.
Recently, Karakiewicz et al. [2008] reported a case of neoadjuvant sunitinib treatment of RCC with a tumor thrombus into the right atrium resulting in major thrombus shrinkage, thus facilitating later surgery. This approach may be justified in high-risk patients not amenable to a surgical approach, however, in our experience, neoadjuvant treatment in this setting risks missing the option of a potentially curative surgical approach. Therefore, patients should be informed about the risks and benefits of a surgical approach including the offer to be referred to an experienced center. Naturally, this is also true for patients with locally advanced disease who should not undergo palliative drug treatment instead.
Patients with limited metastatic disease may also be surgically cured. For patients with pulmonary metastases only surgical removal appears safe and curative in more than one third of cases [Assouad et al. 2007 ]. Even after surgery for osseous RCC metastases 5-year survival rates of 35% have been reported [Lin et al. 2007 ]. Since these data are from the pretyrosine kinase inhibitor era these outcomes are mainly attributable to a surgical approach in highly selected patients.
Phase III data on targeted drugs Motzer et al. [2002] identified risk factors that define three risk categories based on observations of patients with mRCC treated with immunotherapy (Table 1) . These risk factors and categories have been used as inclusion criteria and for stratification in the respective Phase III trials. Notably, in most studies only patients with predominant clear-cell histology were included.
All approved targeted drugs have been shown to extend significantly progression-free survival (PFS) or overall survival (OS) of patients with mRCC in large, prospective randomized trials. Sorafenib was shown to prolong PFS in the placebo-controlled phase 3 TARGET trial (5.5 versus 2.8 months, p < 0.001), including 903 patients with low-and intermediate-risk mRCC after the failure of one systemic therapy [Escudier et al. 2007a ]. OS was not significantly different, which was attributed to a crossover effect in the control arm. However, in a secondary OS analysis censoring post-crossover placebo survival data, an OS advantage for sorafenib was determined (14.3 versus 17.8 months, respectively; hazard ratio ¼ 0.78; p ¼ 0.029) [Escudier et al. 2009b ].
Sunitinib demonstrated a benefit in PFS (11 versus 5 months, p < 0.001) compared with interferon-a in a randomized phase 3 trial of 750 treatment-naïve patients mainly with low and intermediate risk (6% with high risk) [Motzer et al. 2007 ]. The longer OS for patients receiving sunitinib approached statistical significance (26.4 versus 21.8 months, p ¼ 0.051). However, OS survival data may be influenced by subsequent therapies in the control arm [Motzer et al. 2009 ].
Bevacizumb, a monoclonal antibody against VEGFR, has been tested in combination with interferon-a in two phase 3 studies with 649 and 732 patients, respectively Escudier et al. 2007b ]. Both studies resulted in enhanced PFS for bevacizumab plus interferon-a compared with interferon-a alone (10.2 versus 5.4 months, p < 0.0001 and 8.5 versus 5.2 months, p < 0.0001). No statistical difference was found for OS in both studies [Escudier et al. 2009a; Rini et al. 2009 ].
Temsirolimus has been studied in a three-arm prospective, randomized trial, which compared temsirolimus 25 mg intravenously (i.v.) once weekly, interferon-a subcutaneously (s.c.) three times weekly (up to 18 MU), and a combination arm with temsirolimus 15 mg i.v. weekly and interferon-a s.c. three times weekly (up to 6 MU). In contrast to other studies only patients with high-risk disease (according to risk factors similar to Memorial Sloan-Kettering Cancer Center criteria) were included and OS was the primary endpoint. Furthermore, patients with non-clear-cell histology were allowed. A statistically significant OS benefit for temsirolimus (25 mg) compared with interferon-a alone was observed (10.9 versus 7.3 months, p ¼ 0.008) [Hudes et al. 2007] .
Everolimus is an oral mTOR inhibitor, which was investigated in a placebo-controlled phase 3 trial including 410 patients with progression after at least one tyrosine kinase inhibitor treatment. Of note, a significant number of patients received more than one other systemic treatment prior to study entry. The primary endpoint of this study was PFS, which was significantly extended by everolimus (4.0 versus 1.9 months, p < 0.0001) [Motzer et al. 2008] . Patients in the placebo arm were allowed to cross over upon disease progression. Thus, OS did not differ significantly between the two arms.
Phase III data for pazopanib, another oral multikinase inhibitor, have only recently been published [Sternberg et al. 2009 ]. Patients with clear-cell mRCC without prior treatment or with one prior cytokine-based treatment were eligible. Median PFS (the primary endpoint) was significantly higher with pazopanib than with placebo (9.2 versus 4.2 months). Pazopanib was approved by the US Food and Drug Administration in October 2009. An ongoing phase 3 head-to-head study comparing it with sunitinib in treatmentnaïve patients will help to identify its future role in patients with mRCC.
The available Phase III clinical trial data have been included in the guidelines of the European Association of Urology, the European Organization for Research and Treatment of Cancer and the National Comprehensive Cancer Network. Accordingly, selection of the appropriate medication should be based on previous therapy if any (first-line versus second-line treatment) and risk status (Table 2) .
Side effects
Targeted therapies are characterized by common side effects among which fatigue, hypertension, and diarrhea occur most frequently with angiogenesis inhibitor therapy. In addition, each molecule is associated with a more or less specific toxicity profile. Sorafenib frequently causes handfoot skin reaction. Treatment with sunitinib may cause fatigue and mucositis more frequently. Although rare, hypothyroidism (6%, most grade 12), thrombocytopenia (8% grade 3), and cardiotoxicity (1% grade 3) have been described as side effects of sunitinib [Gore et al. 2009 ]. Pazopanib has had a favorable toxicity profile, for example, with regard to fatigue. This needs, however, to be confirmed in the ongoing head-to-head comparison with sunitinib.
Intestinal perforation and hemorrhage have been observed under treatment with bevacizumab. However, the relative risk of all-grade (but not high-grade) bleeding events is also increased with sunitinib and sorafenib treatment as described in a recent systematic review [Je et al. 2009 ]. Patients treated with temsirolimus or everolimus may suffer from pneumonitis, myelosuppression, and elevation of blood glucose and lipids.
Grade 3 and 4 toxicities appear more frequently with sunitinib followed by temsirolimus and sorafenib [Bhojani et al. 2008 ]. However, comparisons of different drugs in different studies have to be considered with caution and head-to-head data are not yet available. Adverse reactions resulted in discontinuation of treatment in about one third of patients in a retrospective review of 146 patients receiving angiogenesis inhibitor therapy [Choueiri et al. 2008 ]. This highlights the need for an appropriate management of side effects in order to avoid interruptions of treatment or unnecessary dose reductions.
Role of tumor nephrectomy in patients with synchronous metastases
The impact of tumor nephrectomy is subject to debate for patients with RCC with synchronous metastases. With regard to immunotherapy, two randomized trials have demonstrated a survival benefit for patients undergoing nephrectomy and immunotherapy compared with immunotherapy alone [Flanigan et al. 2004 ]. Correspondingly, of the patients enrolled in phase 3 trials with targeted drugs, approximately 90% previously underwent nephrectomy. Data from the sunitinib expanded access program (EAP) of mRCC suggest that patients with prior nephrectomy treated with sunitinib have a better outcome with regard to objective remission rates, PFS and OS [Szczylik et al. 2008] . Similar data have been obtained in the sorafenib EAP. Thus, tumor nephrectomy prior to the initiation of tyrosine kinase inhibitor therapy remains the standard of care also in patients with synchronous metastases. However, the positive impact of tumor nephrectomy may be limited to patients with low-and intermediate-risk disease since no benefit was found for high-risk patients in a subgroup analysis of the Phase III temsirolimus study.
Drug selection in everyday practice
Randomized clinical trials are generally performed in selected patient populations with rigid inclusion and exclusion criteria. In everyday practice a more heterogeneous population of patients is treated. For example, the median age of patients with RCC is 62 years; however, the proportion of old patients (65 years) in Phase III studies for newly approved drugs ranged from 31 to 37%. Even in the EAPs older patients are underrepresented with 31% and 4042% for the sunitinib and sorafenib EAP, respectively.
Regarding this issue a taskforce of the International Society of Geriatric Oncology recently published a position paper considering the medical treatment of mRCC in the elderly ]. Reviewing all published data, it was determined that in general PFS and OS benefits, as well as the frequency of major toxicities, are independent of age (with no meaningful data available over the age of 85 years). With regard to sorafenib the effect on PFS in the TARGET study was even somewhat higher among elderly patients. In contrast, for patients over 65 years receiving temsirolimus in the pivotal Phase III trial there was no appreciable difference in median OS (8.6 versus 8.3 months), Therapeutic Advances in Urology 2 (1) but the side effect profile was better than in the interferon arm.
It was suggested, however, that older patients receiving sunitinib experience more fatigue. The taskforce also pointed out that the relationship between dose intensity and outcome of sunitinib will have implications for elderly patients in whom the dose needs to be reduced. With regard to bevacizumab (plus interferon), a slight increase in the proportion in the elderly experiencing grade 3 toxicities was suggested ].
In contrast to age, poor performance (Eastern Cooperative Oncology Group (ECOG) score 2) status appears to have a negative impact on outcome. Data from the EAPs for sunitinib and sorafenib suggest lower remission rates, PFS and OS. Similar observations were obtained for patients with brain metastasis; however, the application of the new agents appears to be safe since cerebral hemorrhage was rare [Beck et al. 2009; Gore et al. 2009; Knox et al. 2007 ].
Papillary and chromophobe RCC are the second and third most frequent histologies of kidney cancer, respectively. Data regarding the effect of targeted drugs in this setting are subject to controversial debate [Strumberg, 2008] . With regard to sunitinib and sorafenib EAP data suggest that both drugs have clinical activity that appears, however, to be reduced compared with ccRCC [Beck et al. 2009; Gore et al. 2009; Knox et al. 2007] . In a subgroup analysis (n ¼ 73) of the pivotal temsirolimus study it seems that especially patients with non-clear-cell histology benefit. This is, however, more related to a lack of efficacy of interferon-a in non-ccRCC while temsirolimus can be regarded as equally active [Dutcher et al. 2009 ].
Sequential therapy
Despite the clinical efficacy of targeted therapies in mRCC, long-term remission is rare and progression will unequivocally occur. Furthermore, major toxicities may lead to treatment discontinuation and subsequent second-or third-line therapy. Therefore, sequential therapy has become the center of interest. As mentioned above, sorafenib and everolimus have been demonstrated to extend PFS after the failure of immunotherapy and tyrosine kinase inhibitors, respectively, in Phase III trials. However, several case series support the sequential use of sorafenib and sunitinib, demonstrating a lack of cross resistance [Di Lorenzo et al. 2009; Dudek et al. 2009; Porta et al. 2009; Sablin et al. 2009; Zimmermann et al. 2009; Eichelberg et al. 2008; Shepard et al. 2008; Tamaskar et al. 2008 ].
These retrospective analyses suggest a benefit in terms of PFS in cases first treated with sorafenib. A reason for the latter could be the lower half maximal inhibitory concentration (IC 50 ) of sunitinib compared with sorafenib for the targeted molecules. That means that the concentration of sunitinib needed for inhibition of VEGFR kinases is lower than that of sorafenib, which may lead to clinical efficacy in cases already resistant to sorafenib [Dudek et al. 2009 ]. Another reason for a prolonged PFS in cases starting with sorafenib could be a slightly more favorable toxicity profile concerning grade 3 and 4 side effects [Bhojani et al. 2008] . Of note, patients who received first-line sunitinib were usually younger than those receiving first-line sorafenib suggesting a subtle investigators' perception of better tolerability of the latter drug ].
However, these small series are prone to selection bias and should be considered with caution. For example, patients receiving both drugs sequentially were selected for omitting those who were unable to receive second-or third-line therapy. Furthermore, these retrospective or small singlearm prospective trials are not balanced with regard to age, comorbidities, and risk status. An ongoing prospective Phase III study (the SWITCH trial) comparing the sequence of sunitinib followed by sorafenib and vice versa will elucidate the preferred sequence.
Adjuvant treatment
Despite initial complete surgical removal of the primary tumor, nonmetastatic RCC frequently recurs. Adjuvant therapy is intended to eliminate minimal (nondetectable) residual disease, which is the source of tumor recurrence. However, to date all clinical trials regarding adjuvant immunotherapy in RCC have been essentially negative.
With the advent of the new targeted drugs, interest in adjuvant therapy of RCC has been renewed.
Three major double-blind, placebo-controlled randomized clinical trials with the primary endpoint of disease-free survival are attempting to define the role, if any, of sorafenib and sunitinib in adjuvant treatment of RCC. The S-TRAC study is comparing sunitinib 50 mg on a 4 weeks on/2 weeks off cycle for 1 year with placebo in patients with high-risk RCC of predominant clear-cell histology after removal of the primary tumor.
The two other studies also include patients with non-clear cell tumors. The ASSURE study (ECOG) is comparing nine 6-week cycles of sorafenib, sunitinib (50 mg, 4/2 schedule) and placebo in an estimated 1923 patients with intermediate to very high-risk disease. Patients are stratified with regard to risk category, histology (clear cell versus non-clear cell), performance status (ECOG 0 or 1) and surgical approach (laparoscopy versus open). The SORCE study (Medical Research Council) will compare placebo with 1-and 3-year adjuvant sorafenib therapy in 1656 patients. This study will use the Leibovich score to define patients at intermediate and high risk for recurrence (inclusion criteria). However, results of these adjuvant clinical trials will not be available before 2011.
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